125 related articles for article (PubMed ID: 36170945)
1. Effects of H1-Antihistamines on hepatocellular carcinoma risk in patients with type 2 diabetes mellitus.
Wu SY; Chen WM; Chen YC; Chiang MF; Lee MC; Soong RS
Diabetes Metab; 2023 Jan; 49(1):101393. PubMed ID: 36170945
[TBL] [Abstract][Full Text] [Related]
2. H1-Antihistamines Reduce the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus, Hepatitis C Virus, or Dual Hepatitis B Virus-Hepatitis C Virus Infection.
Shen YC; Hsu HC; Lin TM; Chang YS; Hu LF; Chen LF; Lin SH; Kuo PI; Chen WS; Lin YC; Chen JH; Liang YC; Chang CC
J Clin Oncol; 2022 Apr; 40(11):1206-1219. PubMed ID: 35044851
[TBL] [Abstract][Full Text] [Related]
3. H1-antihistamine use and head and neck cancer risk in type 2 diabetes mellitus.
Chen YN; Chen YL; Chen WM; Chen M; Shia BC; Ko JY; Wu SY
Oncol Res; 2023; 31(1):23-34. PubMed ID: 37303737
[TBL] [Abstract][Full Text] [Related]
4. Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection.
Tsan YT; Lee CH; Ho WC; Lin MH; Wang JD; Chen PC
J Clin Oncol; 2013 Apr; 31(12):1514-21. PubMed ID: 23509319
[TBL] [Abstract][Full Text] [Related]
5. Aspirin decreases hepatocellular carcinoma risk in hepatitis C virus carriers: a nationwide cohort study.
Liao YH; Hsu RJ; Wang TH; Wu CT; Huang SY; Hsu CY; Su YC; Hsu WL; Liu DW
BMC Gastroenterol; 2020 Jan; 20(1):6. PubMed ID: 31918672
[TBL] [Abstract][Full Text] [Related]
6. The impact of type 2 diabetes on the development of hepatocellular carcinoma in different viral hepatitis statuses.
Wang CS; Yao WJ; Chang TT; Wang ST; Chou P
Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2054-60. PubMed ID: 19549812
[TBL] [Abstract][Full Text] [Related]
7. Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: A nationwide nested case-control study.
Kim G; Jang SY; Han E; Lee YH; Park SY; Nam CM; Kang ES
Int J Cancer; 2017 Feb; 140(4):798-806. PubMed ID: 27861855
[TBL] [Abstract][Full Text] [Related]
8. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C.
Arase Y; Kobayashi M; Suzuki F; Suzuki Y; Kawamura Y; Akuta N; Kobayashi M; Sezaki H; Saito S; Hosaka T; Ikeda K; Kumada H; Kobayashi T
Hepatology; 2013 Mar; 57(3):964-73. PubMed ID: 22991257
[TBL] [Abstract][Full Text] [Related]
9. Antidepressant use and hepatocellular carcinoma in patients with hepatitis C who had received interferon therapy: A population-based cohort study.
Chen VC; Lu ML; Yang YH; Weng JC; Chang CC
J Affect Disord; 2019 Jun; 253():147-153. PubMed ID: 31035215
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B and C viruses and survival from hepatocellular carcinoma in the Arkhangelsk region: a Russian registry-based study.
Makarova M; Krettek A; Valkov MY; Grjibovski AM
Int J Circumpolar Health; 2013; 72():20282. PubMed ID: 23687637
[TBL] [Abstract][Full Text] [Related]
11. A case-control study of hepatitis B and C virus infection as risk factors for hepatocellular carcinoma in Henan, China.
Zhang JY; Dai M; Wang X; Lu WQ; Li DS; Zhang MX; Wang KJ; Dai LP; Han SG; Zhou YF; Zhuang H
Int J Epidemiol; 1998 Aug; 27(4):574-8. PubMed ID: 9758109
[TBL] [Abstract][Full Text] [Related]
12. Association of Antihistamine Use with Increased Risk of Esophageal Squamous Cell Carcinoma: A Nationwide, Long-Term Follow-Up Study Using Propensity Score Matching.
Peng JY; Yu YH; Chen WM; Shia BC; Chen M; Wu SY
Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831114
[TBL] [Abstract][Full Text] [Related]
13. Proton Pump Inhibitors and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B or C.
Kao WY; Su CW; Chia-Hui Tan E; Lee PC; Chen PH; Tang JH; Huang YH; Huo TI; Chang CC; Hou MC; Lin HC; Wu JC
Hepatology; 2019 Mar; 69(3):1151-1164. PubMed ID: 30175498
[TBL] [Abstract][Full Text] [Related]
14. Influence of Metabolic Risk Factors on Risk of Hepatocellular Carcinoma and Liver-Related Death in Men With Chronic Hepatitis B: A Large Cohort Study.
Yu MW; Lin CL; Liu CJ; Yang SH; Tseng YL; Wu CF
Gastroenterology; 2017 Oct; 153(4):1006-1017.e5. PubMed ID: 28711626
[TBL] [Abstract][Full Text] [Related]
15. Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes.
Tseng CH
Liver Int; 2018 Nov; 38(11):2018-2027. PubMed ID: 29956875
[TBL] [Abstract][Full Text] [Related]
16. Selective serotonin reuptake inhibitors use and hepatocellular carcinoma in patients with alcohol use disorder.
Chen VC; Lee MJ; Yang YH; Lu ML; Chiu WC; Dewey ME
Drug Alcohol Depend; 2021 Feb; 219():108495. PubMed ID: 33429293
[TBL] [Abstract][Full Text] [Related]
17. 8 years post-marketing surveillance between Asari Radix and hepatocellular carcinoma: Nationwide population-based evidence against an association.
Chen CN; Tsai YT; Lai JN
J Ethnopharmacol; 2019 Oct; 243():112094. PubMed ID: 31323301
[TBL] [Abstract][Full Text] [Related]
18. Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma.
Hsu YC; Ho HJ; Wu MS; Lin JT; Wu CY
Hepatology; 2013 Jul; 58(1):150-7. PubMed ID: 23389758
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus.
Hassan MM; Hwang LY; Hatten CJ; Swaim M; Li D; Abbruzzese JL; Beasley P; Patt YZ
Hepatology; 2002 Nov; 36(5):1206-13. PubMed ID: 12395331
[TBL] [Abstract][Full Text] [Related]
20. Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy.
Hung CH; Lee CM; Wang JH; Hu TH; Chen CH; Lin CY; Lu SN
Int J Cancer; 2011 May; 128(10):2344-52. PubMed ID: 20669224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
